Researchers have discovered a hyperactive cell signal that contributes to tumor growth in primary effusion lymphoma, an aggressive type of non-Hodgkin lymphoma caused by infection with the Kaposi’s sarcoma-associated herpesvirus (human herpesvirus-8). They’ve developed an experimental therapeutic, UNC3810A, to block the signal and slow tumor growth.
Researchers unveil experimental compound to block therapeutic target in blood cancer
Related Posts
Testimonials
May 27, 2026Propecia 2025-2026
September 10, 2025Order Antibiotics online
June 8, 2024
About admin
Now Dr. Jack Straw is in charge of the website, and organizes it so that medical care is available to everyone. In addition, he is an active member of the medical community, regularly attending international conferences and sharing his experience and knowledge.
Dr. Straw is not only a medical professional and website manager, but also a loving husband and father of his beautiful children.
View all posts by admin →